Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Osama Rahma, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Strohbehn IA, Lee M, Seethapathy H, Chute D, Rahma O, Guidon A, Neilan TG, Zlotoff DA, Okin D, Rengarajan M, Reynolds K, Sise ME. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. Am J Kidney Dis. 2020 May 15. PMID: 32417401.
  2. Grover S, Ruan AB, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, Buchbinder EI, Ott PA, Kehl KL, Awad MM, Hodi FS, Rahma OE. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. 2020 May 13; JOP1900672. PMID: 32401685.
  3. Kumar V, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA, Rahma OE. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist. 2020 Jun; 25(6):505-514. PMID: 32043699.
  4. Singh P, Toom S, Avula A, Kumar V, Rahma OE. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020; 7:11-17. PMID: 32104669.
  5. Nabel CS, Severgnini M, Hung YP, Cunningham-Bussel A, Gjini E, Kleinsteuber K, Seymour LJ, Holland MK, Cunningham R, Felt KD, Vivero M, Rodig SJ, Massarotti EM, Rahma OE, Harshman LC. Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. Oncologist. 2019 08; 24(8):1013-1021. PMID: 31088979.
  6. George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer. 2019 08 15; 125(16):2732-2746. PMID: 31017664.
  7. Rahma OE, Hodi FS. The Intersection between Tumor Angiogenesis and Immune Suppression. Clin Cancer Res. 2019 09 15; 25(18):5449-5457. PMID: 30944124.
  8. Frueh M, Rahma OE, Pachynski RK, Mazieres J, Goldschmidt J, Ton TGN, Mhatre SK, Chuo CY, Martinalbo J, Davies J, Juergens R. Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice. Ann Oncol. 2019 Apr; 30 Suppl 2:ii65. PMID: 32131319.
  9. Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019 05; 94(5):563-574. PMID: 30790338.
  10. Elias R, Hartshorn K, Rahma O, Lin N, Snyder-Cappione JE. Aging,?immune senescence,?and immunotherapy:?A comprehensive review. Semin Oncol. 2018 08; 45(4):187-200. PMID: 30539714.
    Citations:    Fields:    
  11. Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, Balboni T, Ott PA, Hodi FS, Schoenfeld JD. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151. PMID: 30227198.
    Citations:    Fields:    
  12. Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:13-19. PMID: 30231401.
    Citations:    Fields:    Translation:Humans
  13. Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018 04 04; 6(1):26. PMID: 29618381.
    Citations: 2     Fields:    
  14. Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL, Rahma OE. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother. 2018 02; 67(2):161-174. PMID: 29052780.
    Citations: 2     Fields:    Translation:Humans
  15. Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clin Cancer Res. 2017 Aug 15; 23(16):4633-4641. PMID: 28465443.
    Citations: 4     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  16. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017 03; 66(3):545-551. PMID: 27816492.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  17. Millard T, Kunk PR, Ramsdale E, Rahma OE. Current debate in the oncologic management of rectal cancer. World J Gastrointest Oncol. 2016 Oct 15; 8(10):715-724. PMID: 27795811.
    Citations: 2     
  18. Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. Int J Cancer. 2016 10 01; 139(7):1648-57. PMID: 27194579.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  19. Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL, Rahma OE. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 2016 05; 8(5):583-600. PMID: 27140411.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  20. Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016; 4:14. PMID: 26981244.
    Citations: 18     Fields:    
  21. Newhook TE, Lindberg JM, Adair SJ, Kim AJ, Stelow EB, Rahma OE, Parsons JT, Bauer TW. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Ann Surg Oncol. 2016 06; 23(6):1993-2000. PMID: 26847682.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  22. Carrera C, Kunk P, Rahma O. Small Cell Carcinoma of the Gallbladder: Case Report and Comprehensive Analysis of Published Cases. J Oncol. 2015; 2015:304909. PMID: 26823665.
    Citations: 3     
  23. Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, Fioravanti S, Walker M, Carey S, Yu Y, Venkatesan AM, Turkbey B, Choyke P, Trepel J, Bollen KC, Steinberg SM, Figg WD, Greten TF. A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterol J. 2015 Oct; 3(5):453-61. PMID: 26535124.
    Citations: 11     
  24. Verla-Tebit E, Rahma OE. Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report. J Gastrointest Oncol. 2015 Jun; 6(3):E52-4. PMID: 26029467.
    Citations: 1     
  25. Ulahannan SV, Rahma OE, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF. Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepat Oncol. 2015 Jan 01; 2(1):39-50. PMID: 25685318.
    Citations: 3     
  26. Rahma OE, Herrin VE, Ibrahim RA, Toubaji A, Bernstein S, Dakheel O, Steinberg SM, Abu Eid R, Mkrtichyan M, Berzofsky JA, Khleif SN. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. J Transl Med. 2014 Dec 16; 12:353. PMID: 25510844.
    Citations: 2     Fields:    Translation:HumansCells
  27. Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. 2014 Nov; 60(5):1637-44. PMID: 24996116.
    Citations: 25     Fields:    Translation:Humans
  28. Gaertner KM, Caldwell SH, Rahma OE. A case of retinal tear associated with use of sorafenib. Front Oncol. 2014; 4:196. PMID: 25105094.
    Citations: 1     
  29. Zakharia Y, Rahma O, Khleif SN. Ovarian cancer from an immune perspective. Radiat Res. 2014 Aug; 182(2):239-51. PMID: 25036981.
    Citations: 1     Fields:    Translation:Humans
  30. Rahma OE, Gammoh E, Simon RM, Khleif SN. Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin Cancer Res. 2014 Sep 15; 20(18):4758-67. PMID: 25037736.
    Citations: 9     Fields:    Translation:Humans
  31. Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM, Khleif SN. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24; 12:55. PMID: 24565030.
    Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
  32. Rahma OE, Burotto M, Do Canto LM, Germanos AA, Haddad BR, Marshall JL. Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence. World J Gastrointest Oncol. 2013 Nov 15; 5(11):198-203. PMID: 24244806.
  33. Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol. 2013 Aug; 24(8):1972-9. PMID: 23670093.
    Citations: 35     Fields:    Translation:Humans
  34. Duffy A, Rahma O, Greten TF. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2013 Apr 01; 132(7):1718. PMID: 22930464.
    Citations: 1     Fields:    Translation:Humans
  35. Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol. 2012; 2:52. PMID: 22655277.
    Citations: 1     
  36. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother. 2012 Mar; 61(3):373-84. PMID: 21927947.
    Citations: 20     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  37. Rahma OE, Khleif SN. Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y). 2011 Aug; 7(8):517-64. PMID: 22298988.
    Citations: 4     
  38. Song JY, Eberle FC, Xi L, Raffeld M, Rahma O, Wilson WH, Dunleavy K, Pittaluga S, Jaffe ES. Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma. Am J Surg Pathol. 2011 May; 35(5):767-72. PMID: 21490448.
    Citations: 1     Fields:    Translation:Humans
  39. Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med. 2010 Jan 28; 8:8. PMID: 20109232.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  40. Achtar MS, Ibrahim R, Herrin VE, Gause B, Steinberg S, Grollman F, Rahma O, Bernstein S, Maruffi C, Berzofsky J, Khleif SN. Pre-immature dendritic cells pulsed with human papillomavirus 16 E7 peptide vaccine in advanced cervical cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):2522. PMID: 27945807.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Rahma's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (133)
Co-Authors (44)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.